MACKENZI HEATON: Open Payments
NPI 1811657034 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,221 in 30 payments from 14 companies in 2025. Trend: 2023 $4,047 · 2024 $2,344 · 2025 $1,221
Food & beverage: $1,221
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $181 |
| Daiichi Sankyo Inc. | 2 | $152 |
| Merck Sharp & Dohme LLC | 2 | $143 |
| Gilead Sciences, Inc. | 2 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Janssen Biotech, Inc. | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 2 | $121 |
| PFIZER INC. | 4 | $101 |
| ARRAY BIOPHARMA INC | 1 | $31 |
| Stemline Therapeutics Inc. | 1 | $25 |
Products named: KISQALI, KEYTRUDA, ICLUSIG, RYBREVANT, IBRANCE, BRAFTOVI, ENHERTU, DATROWAY.
Industry payments across WA — which companies pay providers there.
